SBP-2L Inhibitors
SBP-2L inhibitors are a category of chemical compounds that interact with a specific protein involved in the regulation of cellular processes. The designation "SBP-2L" refers to a subtype of a larger family of proteins known as Sterol Regulatory Element-Binding Proteins (SREBPs), which are transcription factors integral to lipid metabolism. In particular, the SBP-2L variant is characterized by its unique binding domain, which allows it to interact with specific sequences of DNA, thereby controlling the transcription of genes involved in lipid homeostasis. Inhibitors targeting SBP-2L are designed to bind to this protein and modulate its activity, specifically hindering its ability to engage with DNA and thus affecting the expression of genes under its regulatory scope.
From a chemical standpoint, SBP-2L inhibitors are structurally diverse, with each inhibitor having a unique molecular configuration that determines its affinity and specificity for the SBP-2L protein. The design of these inhibitors often involves a meticulous process of optimization to enhance their binding efficiency while reducing off-target interactions with other proteins. The molecular interaction between SBP-2L inhibitors and the SBP-2L protein typically involves the formation of non-covalent bonds, such as hydrogen bonds, hydrophobic interactions, and van der Waals forces, which stabilize the inhibitor-protein complex. These interactions are highly specific to the conformational nuances of the SBP-2L binding domain, which dictates the selectivity of the inhibitor. Advances in structural biology and computational modeling have aided in the understanding of the SBP-2L structure, which in turn has facilitated the rational design of inhibitors that can effectively modulate the activity of this protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
A tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) pathway. Since SBP-2L may be involved in signaling cascades that are regulated by EGFR, inhibition of this pathway by Erlotinib can decrease SBP-2L activity by reducing its phosphorylation or downstream signaling events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that blocks the mammalian target of rapamycin (mTOR) pathway. By inhibiting mTOR, Rapamycin could reduce the activity of SBP-2L if SBP-2L is regulated by mTOR-dependent signaling, leading to decreased anabolic processes and cellular growth signals that might otherwise enhance SBP-2L activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that impedes the phosphatidylinositol 3-kinase (PI3K) pathway. The PI3K/Akt pathway is crucial for many cellular processes, and inhibition by LY294002 might lead to reduced activity of SBP-2L if SBP-2L is downstream of or influenced by PI3K signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that interferes with the mitogen-activated protein kinase (MAPK) pathway. If SBP-2L activity is contingent upon MAPK signaling, then PD98059 could indirectly inhibit SBP-2L by preventing the activation of downstream targets within this pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that can alter chromatin structure and gene expression. If the expression of SBP-2L is regulated by acetylation status, Trichostatin A could downregulate SBP-2L expression by altering the transcriptional landscape. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that could inhibit SBP-2L if SBP-2L function is modulated by p38 MAPK-dependent signaling pathways, leading to an alteration of stress response pathways in which SBP-2L may be involved. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor like LY294002, which can suppress the PI3K/Akt pathway. Wortmannin's inhibition of PI3K could decrease SBP-2L activity if SBP-2L is influenced by this pathway, affecting a variety of cellular processes including growth and survival. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A BCR-ABL tyrosine kinase inhibitor, also known to affect c-Kit and PDGFR pathways. If SBP-2L is involved in cellular pathways regulated by these kinases, Imatinib could indirectly reduce SBP-2L signaling and activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which may lead to reduced activity of SBP-2L if SBP-2L is a part of or affected by JNK signaling, impacting cellular stress and inflammatory responses. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Another MEK inhibitor that could lead to decreased SBP-2L activity by impeding MAPK/ERK signaling, assuming SBP-2L is regulated by this pathway or has functional interactions with its components. | ||||||